Clinical trials with B-cell-depleting therapies have shown efficacy in both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) and are increasingly perceived as an important addition to the existing panel of disease-modifying treatments (DMTs). Three anti-CD20 targeting monoclonal antibodies have been tested in multiple sclerosis (MS); rituximab (mouse chimeric), ocrelizumab (humanized), and ofatumumab (fully human). Ofatumumab is approved for lymphoma and is currently in phase III testing in RRMS. Given the purpose of this article, it will not be further considered here. Ocrelizumab (Ocrevus, Roche, Basel, Switzerland) was recently approved for RRMS and PPMS both in the United States and Europe. The registration program consisted of a phase II study in RRMS with four arms; ocrelizumab 600 or 2000 mg versus placebo and an open-label interferon-beta (IFNb) arm, 1 followed by two phase III studies in RRMS evaluating 600 mg of ocrelizumab every 6 months against IFNb. 2 In addition, a placebo-controlled phase III trial has been conducted in PPMS with the same dosing of ocrelizumab. 3 In contrast, the development program for ocrelizumab in rheumatoid arthritis (RA) has been terminated and a negative safety signal for serious infections was evident in the phase III study. 4 Rituximab (MabThera, Roche, Basel, Switzerland) is approved for nonHodgkin's lymphoma, chronic lymphocytic leukemia, certain forms of vasculitis and RA with first marketing approval in 1998. Rituximab has undergone clinical testing for MS in a phase II placebocontrolled trial for RRMS and a phase II/III trial PPMS, 5,6 after which further clinical development for these indications was interrupted by the manufacturer. Still, during recent years off-label use of rituximab for treating MS has increased in countries where this is possible, where Sweden stands out with an approximate 40% share of all ongoing DMT. The question that arises with the access of an approved anti-CD20 DMT is whether continued use of rituximab can be justified by medical arguments, leaving legal and cost issues aside.
Clinical trials with B-cell-depleting therapies have shown efficacy in both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) and are increasingly perceived as an important addition to the existing panel of disease-modifying treatments (DMTs). Three anti-CD20 targeting monoclonal antibodies have been tested in multiple sclerosis (MS); rituximab (mouse chimeric), ocrelizumab (humanized), and ofatumumab (fully human). Ofatumumab is approved for lymphoma and is currently in phase III testing in RRMS. Given the purpose of this article, it will not be further considered here. Ocrelizumab (Ocrevus, Roche, Basel, Switzerland) was recently approved for RRMS and PPMS both in the United States and Europe. The registration program consisted of a phase II study in RRMS with four arms; ocrelizumab 600 or 2000 mg versus placebo and an open-label interferon-beta (IFNb) arm, 1 followed by two phase III studies in RRMS evaluating 600 mg of ocrelizumab every 6 months against IFNb. 2 In addition, a placebo-controlled phase III trial has been conducted in PPMS with the same dosing of ocrelizumab. 3 In contrast, the development program for ocrelizumab in rheumatoid arthritis (RA) has been terminated and a negative safety signal for serious infections was evident in the phase III study. 4 Rituximab (MabThera, Roche, Basel, Switzerland) is approved for nonHodgkin's lymphoma, chronic lymphocytic leukemia, certain forms of vasculitis and RA with first marketing approval in 1998. Rituximab has undergone clinical testing for MS in a phase II placebocontrolled trial for RRMS and a phase II/III trial PPMS, 5, 6 after which further clinical development for these indications was interrupted by the manufacturer. Still, during recent years off-label use of rituximab for treating MS has increased in countries where this is possible, where Sweden stands out with an approximate 40% share of all ongoing DMT. The question that arises with the access of an approved anti-CD20 DMT is whether continued use of rituximab can be justified by medical arguments, leaving legal and cost issues aside.
To us, the medical arguments can be subdivided into three issues; efficacy, immunogenicity, and safety. With regard to efficacy, we find the data of three recent comparative effectiveness studies of particular interest. The first study compared rituximab to fingolimod in RRMS patients switching from natalizumab, showing a clearly superior effect and overall drug survival, as well as a more beneficial safety profile 7 Discontinuation of natalizumab has been associated with a rebound in disease activity in patients with highly active disease and the striking difference between rituximab and fingolimod in this context was notable. In the second study, rituximab was compared to other DMT in a population-based sample of treatment naive RRMS, showing superior drug survival over all other DMT included in the analysis, including numerically lower relapse rates than natalizumab. 8 Third, a registry study of 461 RRMS patients treated with rituximab, propensity matched to patients receiving either IFNb or glatiramer acetate, showed a compelling 87% advantage of rituximab in reducing relapse rate. 9 Furthermore, ocrelizumab and rituximab have both been tested in PPMS. In the Olympus study, treatment with rituximab compared to placebo was associated with a reduction in the proportion of patients with 12 weeks confirmed disability progression with 8.3 percentage points (p = 0.14), while the corresponding figure for ocrelizumab in Oratorio was 6.4 percentage points (p = 0.03). Collectively, these findings strongly support the notion of a high efficacy of rituximab in RRMS even in real-world situations for which controlled trial data are lacking, as well as a similar effect size in PPMS as for ocrelizumab.
Regarding immunogenicity, it is acknowledged that anti-drug antibodies (ADAs) may impact negatively on efficacy and tolerability of biological drugs. 10 In three trials of rituximab in MS, ADA was found in 25% and 29% of RRMS patients and 7% in PPMS; however, there was no clear correlation with clinical outcomes. 5, 6, 11 More recently, using two different assays, ADA was detectable in 37% of RRMS and 26% in progressive forms of MS with a more sensitive assay, but with decreasing percentages with increasing number of rituximab infusions. 12 There was a significant association between presence and titers of ADA, and incomplete B-cell depletion, but not with infusion/adverse reactions or clinical outcomes at the group level. With regard to ocrelizumab, anti-drug-binding antibodies were found in 0.4% and 1.9% of RRMS and PPMS patients, respectively, with only one patient in each group developing neutralizing antibodies. 2, 3 While these findings clearly suggest that rituximab is more immunogenic than ocrelizumab, some caution is warranted since assay methods differ between the studies. More importantly, there are still not enough data to evaluate the clinical significance of ADA in patients treated with rituximab.
Last, regarding safety, the Food and Drug Administration (FDA) has highlighted risks with infusion reactions, serious infections, and malignancies with ocrelizumab. 13 The number of detected malignancies was doubled in active arms of the phase III program; however, risks are difficult to correctly assess with observation times of only a few years. In contrast, rituximab has been used for other indications for almost two decades and no serious concerns for increased risks of cancer have arisen. For example, in a recent nation-wide RA cohort study, no signal for increased incidence of malignancies with rituximab was detected. 14 Still, extrapolation to MS should be done with caution due to differences in patient populations and administration regimens. There is also a question about of dosing. In RA, a treatment cycle consists of two 1000-mg doses 2 weeks apart, a dosing regimen, repeated every 6 months, used also in the controlled trials for MS. 5, 6, 11 In the observational studies referred to above, the dosing was either a single infusion of 500 or 1000 mg repeated every 6 months. [7] [8] [9] Furthermore, when comparing the two doses, no differences in efficacy outcomes were noted, but a trend for better tolerability with the lower dose. 15 In the MS phase II study, ocrelizumab was tested in two doses: 600 and 2000 mg. 1 Since the lower dose was equally effective, only the 600-mg dose was used in the phase III studies. In RA, ocrelizumab has been tested alone or in combination with methotrexate in doses up to 1000 mg, where higher rates of serious and opportunistic infections, some of which resulted in death, have been recorded with doses ≥ 500 mg. 4 Collectively, we see continued use of rituximab in MS as justified given the established safety record of rituximab and accumulating evidence from comparative effectiveness studies in real-world populations that includes patients with high risk of disease breakthrough, and taking into consideration also the safety concerns that have arisen in the development program for ocrelizumab. Stringent prospective follow-up is, however, clearly motivated to allow for future comparative effectiveness studies between the two drugs. Finally, it is of interest to note that a recent meta-analysis failed to show that off-label medications proved less efficacious than approved drug treatments in randomized trials, suggesting that evidence-based treatment decisions should include all available options regardless of labeling status. 16 
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Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis -No Mitchell 
T Wallin
The success of B cell-directed therapy in patients with multiple sclerosis (MS) has been highlighted and demonstrates the essential role these cells have in the pathogenesis of MS. 1 The chimeric anti-CD20 monoclonal antibody (mAb) rituximab (RTX) was the first anti-CD20 to be licensed for use in humans. RTX has shown promise in phase II clinical trials in relapsing remitting multiple sclerosis (RRMS) 2 as well as observational MS trials. 3, 4 More recently, the humanized anti-CD20 mAb ocrelizumab (OCR) was tested in phase III trials for relapsing MS and primary progressive multiple sclerosis (PPMS). 5, 6 These pivotal trials provided the support for the US Food and Drug Administration (FDA) to license OCR for both PPMS and relapsing forms of MS in March 2017.
Controversy has arisen as to whether RTX should be an acceptable replacement for OCR. While there is an FDA indication for RTX in the US for specific malignancies and rheumatoid arthritis, the use of RTX as an MS therapy would be considered "off-label." Arguments have been made regarding equivalent efficacy, safety, and convenience between RTX and OCR. However, there is a significant difference in cost, which is substantially lower for RTX. The author contrasts the use of RTX and OCR for MS within these topical areas to show the unique niche for OCR at the present time in the US health care system.
In terms of molecular structure, OCR binds to the extracellular loop of the CD20 epitope on B cells, 5 
